Evan Stein

Summary

Publications

  1. ncbi Safety of rosuvastatin
    James Shepherd
    Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland
    Am J Cardiol 94:882-8. 2004
  2. ncbi Are LDL subclass measurements clinically relevant?
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45229, USA
    Nat Clin Pract Endocrinol Metab 2:120-1. 2006
  3. ncbi Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin
    Evan Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio 45229, USA
    Am Heart J 148:447-55. 2004
  4. doi Effect of a monoclonal antibody to PCSK9 on LDL cholesterol
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, 4685 Forest Ave, Cincinnati, OH 45212, USA
    N Engl J Med 366:1108-18. 2012
  5. ncbi Targeting LDL: is lower better and is it safe?
    Evan A Stein
    Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45215, USA Electronic address
    Best Pract Res Clin Endocrinol Metab 28:309-24. 2014
  6. doi Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9
    Evan A Stein
    Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio 45215 email
    Annu Rev Med 65:417-31. 2014
  7. doi Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics
    Evan A Stein
    Metabolic and Atherosclerosis Research Center and Medpace Reference Laboratories, 5355 Medpace Way, Cincinnati, OH, USA
    Curr Atheroscler Rep 15:310. 2013
  8. doi Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibiti
    Frederick Raal
    Carbohydrate and Lipid Metabolism Research Unit, Division of Endocrinology and Metabolism, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa
    Circulation 126:2408-17. 2012
  9. doi Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, 5355 Medpace Way, Cincinnati, OH 45227, USA
    Circulation 126:2283-92. 2012
  10. doi Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlle
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45212, USA
    Lancet 380:29-36. 2012

Detail Information

Publications63

  1. ncbi Safety of rosuvastatin
    James Shepherd
    Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland
    Am J Cardiol 94:882-8. 2004
    ..Rosuvastatin was well tolerated by a broad range of patients who had dyslipidemia, and its safety profile was similar to those of the comparator statins investigated in this extensive clinical program...
  2. ncbi Are LDL subclass measurements clinically relevant?
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45229, USA
    Nat Clin Pract Endocrinol Metab 2:120-1. 2006
  3. ncbi Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin
    Evan Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio 45229, USA
    Am Heart J 148:447-55. 2004
    ....
  4. doi Effect of a monoclonal antibody to PCSK9 on LDL cholesterol
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, 4685 Forest Ave, Cincinnati, OH 45212, USA
    N Engl J Med 366:1108-18. 2012
    ..We report three phase 1 studies of a monoclonal antibody to PCSK9 designated as REGN727/SAR236553 (REGN727)...
  5. ncbi Targeting LDL: is lower better and is it safe?
    Evan A Stein
    Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45215, USA Electronic address
    Best Pract Res Clin Endocrinol Metab 28:309-24. 2014
    ..Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors which will reduce LDL-C well below 1.3 mmol/L, will likely provide the clearest answer to both the question of efficacy and safety of low LDL-C within the next few years. ..
  6. doi Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9
    Evan A Stein
    Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio 45215 email
    Annu Rev Med 65:417-31. 2014
    ....
  7. doi Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics
    Evan A Stein
    Metabolic and Atherosclerosis Research Center and Medpace Reference Laboratories, 5355 Medpace Way, Cincinnati, OH, USA
    Curr Atheroscler Rep 15:310. 2013
    ..Larger and much longer phase 3 trials are now in progress to assess the long-term tolerability, safety, and impact on cardiovascular disease events of these very effective LDLc lowering compounds...
  8. doi Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibiti
    Frederick Raal
    Carbohydrate and Lipid Metabolism Research Unit, Division of Endocrinology and Metabolism, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa
    Circulation 126:2408-17. 2012
    ..This phase 2, multicenter, double-blind, randomized, placebo-controlled, dose-ranging study evaluated the efficacy and safety of AMG 145 in heterozygous familial hypercholesterolemia patients...
  9. doi Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, 5355 Medpace Way, Cincinnati, OH 45227, USA
    Circulation 126:2283-92. 2012
    ..We evaluated mipomersen, an apolipoprotein B synthesis inhibitor, to further lower LDL-C in HeFH patients with coronary artery disease...
  10. doi Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlle
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45212, USA
    Lancet 380:29-36. 2012
    ..We assessed the efficacy and safety of various doses and dosing intervals of REGN727, a monoclonal antibody to PCSK9, added to statins, to further lower LDL-C in patients with heterozygous familial hypercholesterolaemia...
  11. doi Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program
    Evan A Stein
    Medpace Reference Laboratories, Inc, 4620 Wesley Avenue, Cincinnati, OH 45212, USA
    Atherosclerosis 221:471-7. 2012
    ..We assessed the effects of rosuvastatin on the risk of developing renal impairment or renal failure among participants in the rosuvastatin clinical development program...
  12. ncbi Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH, USA
    Am J Cardiol 100:1387-96. 2007
    ..In conclusion, long-term treatment with rosuvastatin 40 mg is safe and effective in patients with severe hypercholesterolemia...
  13. ncbi Fluvastatin treatment is not associated with an increased incidence of cancer
    E A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45229, USA
    Int J Clin Pract 60:1028-34. 2006
    ..995-1.000; p = 0.107). In conclusion, fluvastatin treatment is not associated with an increased risk of cancer compared with placebo in clinical trials, independent of patient age, treatment duration and baseline cholesterol levels...
  14. doi Adult treatment panel III and the management of dyslipidemia risk factors
    Evan A Stein
    University of Cincinnati, Highland Heights, KY 41076, USA
    Postgrad Med 112:12-7. 2002
    ..As a result, many more individuals have been identified as requiring intervention, and others will require more aggressive modalities, including cholesterol lowering pharmacotherapy...
  15. ncbi Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio 41075, USA
    Am J Cardiol 96:36K-43K; discussion 34K-35K. 2005
    ..This article reviews the use of these 3 biomarkers in assessing cardiovascular risk, and the strategies for managing combined hyperlipidemia...
  16. ncbi Statins in children. Why and when
    E A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Nutr Metab Cardiovasc Dis 11:24-9. 2001
    ..While additional well-controlled studies are needed, especially those focusing on surrogates of atherosclerosis to determine clinical benefit, it is opportune for re-evaluation of current treatment guidelines...
  17. doi Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Am J Cardiol 101:490-6. 2008
    ..In conclusion, in patients with a history of statin-associated MRSEs, fluvastatin XL alone or in combination with ezetimibe offers an effective and well-tolerated lipid-lowering option...
  18. ncbi After ENHANCE: is more LDL cholesterol lowering even better?
    Evan A Stein
    Medpace Reference Labs, Cincinnati, OH 45212, USA
    Clin Chem 54:940-2. 2008
  19. doi Other therapies for reducing low-density lipoprotein cholesterol: medications in development
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, 4685 Forest Avenue, Cincinnati, OH, USA
    Endocrinol Metab Clin North Am 38:99-119. 2009
    ..Although most of the effective lipid-lowering drugs, the statins, have become generic and inexpensive, there remains a need for effective and safe agents. Hopefully, some of those discussed in this article will fill that need...
  20. ncbi Safety and tolerability of dalcetrapib
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH, USA
    Am J Cardiol 104:82-91. 2009
    ....
  21. doi Future trends in the treatment of dyslipidemia. Introduction
    Evan A Stein
    University of Cincinnati, Highland Heights, KY 41076, USA
    Postgrad Med 112:4-5. 2002
    ..In turn, of these sudden deaths, almost half died before they reached medical attention at a hospital, and of those who did reach a hospital, 16.5% either were dead on arrival or died in the emergency room...
  22. doi Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, 4685 Forest Ave, Suite A, Cincinnati, OH 45212, USA
    J Pediatr 156:231-6.e1-3. 2010
    ..Evaluate the efficacy and safety of colesevelam hydrochloride in children with heterozygous familial hypercholesterolemia (heFH)...
  23. pmc Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45212, USA
    Eur Heart J 31:480-8. 2010
    ....
  24. doi Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, OH 45212, USA
    Circulation 123:1974-85. 2011
    ..Lapaquistat acetate is a squalene synthase inhibitor investigated for the treatment of hypercholesterolemia...
  25. ncbi Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Am J Cardiol 92:1287-93. 2003
    ....
  26. ncbi Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial
    E A Stein
    Medical Research Laboratories, Highland Heights, KY, USA
    JAMA 281:137-44. 1999
    ..The age at which drug therapy should be started is still controversial, as is the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)...
  27. ncbi Management of dyslipidemia in the high-risk patient
    Evan A Stein
    Metabolic and Atherosclerosis Research Center and Medical Research Laboratories International, Cincinnati, Ohio 45229, USA
    Am Heart J 144:S43-50. 2002
    ..It is anticipated that such new options will allow clinicians to optimize the management of dyslipidemia in high-risk patients, thereby reducing the morbidity and mortality of CHD...
  28. ncbi The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment
    Evan Stein
    Metabolic and Atherosclerosis Research Center, Suite 201, Medical Office Building East, 3131 Harvey Avenue, Cincinnati, OH 45229, USA
    Atheroscler Suppl 2:19-23; discussion 23-5. 2002
    ....
  29. ncbi Managing dyslipidemia in the high-risk patient
    Evan A Stein
    Medical Research Laboratories International, Highland Heights, Kentucky 41076, USA
    Am J Cardiol 89:50C-57C. 2002
    ..It is anticipated that these new options will allow clinicians to optimize the management of dyslipidemia in high-risk patients, thereby further reducing the morbidity and mortality of CAD...
  30. ncbi Introduction: rosuvastatin--an efficacy assessment based on pooled trial data
    Evan A Stein
    MRL International, Highland Heights, Kentucky 41076, USA
    Am J Cardiol 91:1C-2C. 2003
  31. ncbi Lipoprotein changes with statins
    Evan A Stein
    Medical Research Laboratories International, 2 Tesseneer Avenue, Highland Heights, KY 41076, USA
    Curr Atheroscler Rep 4:14-8. 2002
    ..In addition, some recent papers have focused on new parameters that may mediate cardiovascular risk, such as high-sensitivity C-reactive protein...
  32. ncbi Laboratory surrogates for anti-atherosclerotic drug development
    E Stein
    Medical Research Laboratories, Highland Heights, Kentucky 41076, USA
    Am J Cardiol 87:21A-26A. 2001
    ..All of these parameters are involved in either the causation or propagation of the atherothrombotic process...
  33. ncbi Aggressive treatment of dyslipidemia: a review of supporting evidence
    E A Stein
    Medical Research Laboratories, Highland Heights, Kentucky 41076, USA
    Cleve Clin J Med 68:130-1, 135-6, 137-8, 141-2. 2001
    ..Of the available cholesterol-lowering agents, statins produce the greatest reductions in LDL-C levels and coronary events and are currently the best treatment option for most patients...
  34. ncbi New statins and new doses of older statins
    E A Stein
    Medical Research Laboratories, 2 Tesseneer, Highland Heights, KY 41076, USA
    Curr Atheroscler Rep 3:14-8. 2001
    ....
  35. ncbi Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia
    E Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio 45219, USA
    Am J Cardiol 83:1433-6. 1999
    ..The increased efficacy and lack of clinically significant laboratory abnormalities or adverse events demonstrates a need for a large long-term study to confirm the safety and efficacy of this dose of cerivastatin...
  36. ncbi Lipid modulation and atherosclerotic events: extending the clinical spectrum with fibrates and statins
    E A Stein
    Medical Research Laboratories, 2 Tesseneer Drive, Highland Heights, KY 41076, USA
    Curr Atheroscler Rep 2:11-3. 2000
    ..These include primary and secondary prevention of CAD in the elderly, primary prevention of CAD in persons with diabetes, and primary prevention of stroke...
  37. ncbi The power of statins: aggressive lipid lowering
    Evan A Stein
    Medical Research Laboratories International, Cincinnati, Ohio, USA
    Clin Cardiol 26:III25-31. 2003
    ..A novel class of agents, cholesterol transport inhibitors, have recently become available. These and other new agents hold promise to help achieve ATP III goals when used in combination regimens initiated with a statin...
  38. ncbi Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
    Jonathan Isaacsohn
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Clin Cardiol 26:18-24. 2003
    ....
  39. ncbi The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Postgrad Med 121:145-50. 2009
    ..Thus, the 4-g/day dose contributes approximately 44 Cal/day, with approximately 36 Cal/day derived from the oil...
  40. doi Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY 40213, USA
    Curr Med Res Opin 26:907-15. 2010
    ..Assess the long-term efficacy and safety of prescription omega-3-acid ethyl esters (P-OM3) coadministered with simvastatin in an extension of the Combination of Prescription Omega-3 Plus Simvastatin (COMBOS) trial...
  41. pmc Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Ave, Louisville, KY 40213, USA
    Mayo Clin Proc 85:122-8. 2010
    ..To evaluate the effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol (HDL-C) levels in atorvastatin-treated patients with elevated non-HDL-C and triglyceride levels...
  42. ncbi Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia
    J Isaacsohn
    Medpace, Cincinnati, Ohio 45212, USA
    Clin Cardiol 24:IV1-9. 2001
    ..Statins are the agents of choice in reducing elevated plasma low-density lipoprotein cholesterol (LDL-C)...
  43. ncbi An investigative look: selective cholesterol absorption inhibitors--embarking on a new standard of care
    Evan A Stein
    Cholesterol Treatment Center, Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Am J Manag Care 8:S36-9; discussion S45-7. 2002
    ..Larger, long-term phase 3 trials confirmed the efficacy and safety of the 10-mg dose and also demonstrated that ezetimibe monotherapy is an excellent alternative for patients who cannot tolerate statins...
  44. ncbi Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia
    Michael Davidson
    Chicago Center for Clinical Research, Chicago, Illinois, USA
    Am J Cardiol 89:268-75. 2002
    ..Both treatments were well tolerated...
  45. ncbi Identification and treatment of individuals at high risk of coronary heart disease
    Evan A Stein
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Am J Med 112:3S-9S. 2002
    ..Other options that may soon be available as additive agents to statins to achieve greater LDL cholesterol reductions include bile acid transport inhibitors and cholesterol absorption inhibitors...
  46. ncbi Patients with acute coronary syndromes should received statins
    Donald M Black
    Department of Pediatric Cardiology, University of Michigan The Cholesterol Treatment Center, Cincinnati, Ohio Medical Research Laboratories, 2 Tesseneer, Highland Heights, KY 41076, USA
    Curr Atheroscler Rep 4:11-3. 2002
  47. ncbi Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients
    Harold E Bays
    L MARC Research Center, Louisville, Kentucky, USA
    Am J Cardiol 90:942-6. 2002
    ..Simvastatin had no effect on VCAM, SAA, or IL-6. In summary, simvastatin significantly reduced CRP in patients with mixed hyperlipidemia and hypertriglyceridemia...
  48. ncbi Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
    Peter H Jones
    Baylor College of Medicine, 6565 Fannin Avenue, A 601, Houston, TX 77030, USA
    Am J Cardiol 92:152-60. 2003
    ..0 mmol/L was achieved by 79% to 92% in rosuvastatin groups compared with 52% to 81% in atorvastatin groups. Drug tolerability was similar across treatments...
  49. ncbi Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia
    Donald B Hunninghake
    Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Coron Artery Dis 15:115-23. 2004
    ..We examined the effects of rosuvastatin treatment on triglyceride levels and lipid measures in a parallel-group multicenter trial (4522IL/0035) in patients with hypertriglyceridemia (Fredrickson Type IIb or IV)...
  50. ncbi Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy
    James Shepherd
    Glasgow Royal Infirmary, Glasgow, Scotland, UK
    Curr Med Res Opin 20:1571-8. 2004
    ..To evaluate the efficacy and safety of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy (HRT) in a randomized, double-blind, placebo-controlled trial...
  51. ncbi Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial
    Peter H Jones
    Section of Atherosclerosis and Lipid Research, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Ther 26:1388-99. 2004
    ....
  52. ncbi Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome
    Christie M Ballantyne
    Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas, USA
    Am J Cardiol 91:25C-27C; discussion 28C. 2003
    ..Among patients who met the metabolic syndrome criteria and who had triglycerides > or =200 mg/dL, 64% met their ATP III non-HDL goals...
  53. ncbi Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups
    James W Blasetto
    AstraZeneca LP, Wilmington, Delaware 19850, USA
    Am J Cardiol 91:3C-10C; discussion 10C. 2003
    ....
  54. ncbi Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II
    Christie M Ballantyne
    Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, TX, USA
    Am Heart J 151:975.e1-9. 2006
    ..This target can be difficult to attain with diet and current therapy...
  55. ncbi Risk for myopathy with statin therapy in high-risk patients
    Christie M Ballantyne
    Center for Cardiovascular Disease Prevention, Baylor College of Medicine, 6565 Fannin, Mail Station A601, Suite A656, Houston, TX 77030, USA
    Arch Intern Med 163:553-64. 2003
    ..Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease...
  56. ncbi A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia
    A David Marais
    Groote Schuur Hospital and University of Cape Town, Lipidology, Internal Medicine, 5th Floor C Barnard Building, UCT Health Science Faculty, Anzio Road, Cape Town 7925, South Africa
    Atherosclerosis 197:400-6. 2008
    ..All treatments were well tolerated. Rosuvastatin may have therapeutic value in the management of hoFH...
  57. ncbi Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study
    Michael H Davidson
    Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    Clin Ther 29:1354-67. 2007
    ..The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) has identified non-HDL-C as a secondary therapeutic target in these patients, but treatment goals may not be reached with statin monotherapy alone...
  58. doi Simvastatin with or without ezetimibe in familial hypercholesterolemia
    John J P Kastelein
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    N Engl J Med 358:1431-43. 2008
    ..Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown...
  59. ncbi Pharmacotherapy for dyslipidaemia--current therapies and future agents
    Harold Bays
    L MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Opin Pharmacother 4:1901-38. 2003
    ..Finally, current and future lipid-altering drugs may include anti-obesity agents which could favourably affect lipid levels...
  60. ncbi CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group
    Gary L Myers
    Circulation 110:e545-9. 2004
  61. ncbi Are measurements of LDL particles ready for prime time?
    Evan A Stein
    Clin Chem 52:1643-4. 2006
  62. ncbi Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk
    Wim A van der Steeg
    Academic Medical Center, Amsterdam, The Netherlands
    Ann Intern Med 146:640-8. 2007
    ..It is not known whether this ratio is better than traditional lipid values for risk assessment and prediction and whether it adds predictive value to the Framingham risk score...
  63. ncbi Statins and children: whom do we treat and when?
    Evan A Stein
    Circulation 116:594-5. 2007